Entyce 30mg/ml Oral Solution

Stimulates Appetite in Dogs Effectively

Product Description

ENTYCE is a veterinarian-prescribed oral solution designed to stimulate appetite in dogs. Formulated with capromorelin, a selective ghrelin receptor agonist, it works by targeting appetite pathways in the brain and supporting growth hormone release. Given once daily, this flavored liquid is easy to administer using the provided syringe and is FDA approved for appetite stimulation in dogs.

Benefits

• Clinically Proven Appetite Support: Demonstrated statistically significant increase in food consumption compared to control in clinical studies.
• Selective Ghrelin Agonist: Works by targeting ghrelin receptors in the hypothalamus to stimulate appetite through the body’s natural signaling pathways.
• Supports Growth Hormone Release: Binds to growth hormone secretagogue receptors in the pituitary gland to increase growth hormone production.
• Convenient Once Daily Dosing: Give by mouth once a day at a dose of 3 mg for every kilogram of body weight.
• FDA-Approved for Dogs: Approved under NADA 141-457 for appetite stimulation in dogs.

Variants

• 10mL bottle
• 15mL bottle
• 30mL bottle

Ingredients

Composition Table

Additional Information

Precautions

• Hepatic Caution: Use cautiously in dogs with hepatic dysfunction due to CYP3A4 and CYP3A5 metabolism.
• Renal Caution: Use cautiously in dogs with renal insufficiency due to partial urinary excretion.
• Breeding Safety Unknown: Safe use not evaluated in breeding dogs or pregnant and lactating bitches.
• Human Safety Warning: Not for human use and should be kept out of reach of children.

Possible Side Effects

• Diarrhea and Vomiting: Some dogs experienced stomach issues such as diarrhea and vomiting during clinical studies.
• Hypersalivation: A few dogs showed increased drooling in controlled field studies.
• Increased Thirst: Some treated dogs drank more water than usual during safety studies.
• Lethargy or Depression: A small number of dogs appeared mildly tired or less active.
• Elevated Blood Values: In some cases, lab tests showed higher levels of blood urea nitrogen, phosphorus, or creatinine.

Storage Information

• Temperature Limit: Store at or below 86°F or 30°C to maintain product stability.
• Secure Storage: Keep medication out of reach of children and pets.

Shipping & Return

We offer ground, express, priority, and international delivery; see our shipping policy for details.

For return instructions or product concerns, please refer to our detailed refund policy. 

Prescription items are NON-RETURNABLE and NON-REFUNDABLE.  

Frequently Asked Questions

Q1: What is ENTYCE used for in dogs?

Ans: ENTYCE is FDA approved for appetite stimulation in dogs. It contains capromorelin, a selective ghrelin receptor agonist that works by stimulating appetite through receptors in the hypothalamus. It is prescribed by veterinarians for dogs experiencing reduced or absent appetite.

Q2: How does ENTYCE stimulate appetite in dogs?

Ans: ENTYCE works by activating ghrelin receptors in the hypothalamus, which are involved in regulating hunger signals. It also attaches to growth hormone secretagogue receptors located in the pituitary gland, which stimulates the release of growth hormone as part of its therapeutic effect.

Q3: What is the recommended dosage of ENTYCE for dogs?

Ans: The recommended dosage of ENTYCE is 3 mg per kg body weight, or 1.4 mg per lb, administered orally once daily. The bottle should be gently shaken before use, and the provided syringe should be used to measure the prescribed amount.

Q4: Is ENTYCE safe for long-term use in dogs?

Ans: Effectiveness has been evaluated in clinical field studies for up to four days. A 12-month laboratory safety study assessed various dose levels, with no drug accumulation observed, though certain dose-related changes were reported at higher exposure levels.

Q5: What side effects can occur with ENTYCE?

Ans: Reported adverse reactions include diarrhea, vomiting, hypersalivation, increased thirst, and mild lethargy. Some dogs also showed changes in blood parameters, such as elevated blood urea nitrogen or phosphorus, during controlled field studies.